07:52 AM EDT, 10/10/2024 (MT Newswires) -- Pfizer ( PFE ) said Thursday that results from a phase 3 trial of Talzenna (talazoparib) combined with Xtandi (enzalutamide) to treat metastatic castration-resistant prostate cancer showed a "statistically significant and clinically meaningful improvement" in overall survival compared with Xtandi alone.

Under an agreement signed in 2009, Pfizer ( PFE ) is jointly responsible for commercializing Xtandi in the US with Japanese pharmaceutical company Astellas Pharma. Astellas also has responsibility for manufacturing, regulatory filings, and commercializing Xtandi outside the US.

Price: 29.80, Change: -0.39, Percent Change: -1.29